SG11201600028YA - Substituted aminopyrimidine compounds and methods of use - Google Patents

Substituted aminopyrimidine compounds and methods of use

Info

Publication number
SG11201600028YA
SG11201600028YA SG11201600028YA SG11201600028YA SG11201600028YA SG 11201600028Y A SG11201600028Y A SG 11201600028YA SG 11201600028Y A SG11201600028Y A SG 11201600028YA SG 11201600028Y A SG11201600028Y A SG 11201600028YA SG 11201600028Y A SG11201600028Y A SG 11201600028YA
Authority
SG
Singapore
Prior art keywords
methods
use
aminopyrimidine compounds
substituted aminopyrimidine
substituted
Prior art date
Application number
SG11201600028YA
Inventor
Ning Xi
Liang Wang
Zuping Wu
Xuejin Feng
Yanjun Wu
Original Assignee
Calitor Sciences Llc
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361880974P priority Critical
Priority to US201461983444P priority
Application filed by Calitor Sciences Llc, Sunshine Lake Pharma Co Ltd filed Critical Calitor Sciences Llc
Priority to PCT/US2014/055966 priority patent/WO2015042077A1/en
Publication of SG11201600028YA publication Critical patent/SG11201600028YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/409Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever
SG11201600028YA 2013-09-22 2014-09-17 Substituted aminopyrimidine compounds and methods of use SG11201600028YA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201361880974P true 2013-09-22 2013-09-22
US201461983444P true 2014-04-23 2014-04-23
PCT/US2014/055966 WO2015042077A1 (en) 2013-09-22 2014-09-17 Substituted aminopyrimidine compounds and methods of use

Publications (1)

Publication Number Publication Date
SG11201600028YA true SG11201600028YA (en) 2016-02-26

Family

ID=52689330

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201600707QA SG11201600707QA (en) 2013-09-22 2014-09-17 Substituted aminopyrimidine compounds and methods of use
SG11201600028YA SG11201600028YA (en) 2013-09-22 2014-09-17 Substituted aminopyrimidine compounds and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201600707QA SG11201600707QA (en) 2013-09-22 2014-09-17 Substituted aminopyrimidine compounds and methods of use

Country Status (10)

Country Link
US (4) US9657007B2 (en)
EP (2) EP3046921A4 (en)
JP (2) JP6494634B2 (en)
KR (2) KR20160060100A (en)
AU (2) AU2014321420B2 (en)
CA (2) CA2920059A1 (en)
MX (2) MX2016003456A (en)
RU (2) RU2683793C2 (en)
SG (2) SG11201600707QA (en)
WO (3) WO2015042078A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2683793C2 (en) * 2013-09-22 2019-04-02 Калитор Сайенсез, ЛЛС Substituted aminopyrimidine compounds and methods of use
EP3154961B1 (en) 2014-06-13 2019-10-09 Gilead Sciences, Inc. Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
EA201692267A1 (en) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Phosphatidylinositol-3-kinase inhibitors
AU2015274696B2 (en) * 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
JP6454736B2 (en) 2014-06-13 2019-01-16 ギリアード サイエンシーズ, インコーポレイテッド Phosphatidylinositol 3-kinase inhibitor
SG11201610770PA (en) 2014-07-04 2017-01-27 Lupin Ltd Quinolizinone derivatives as pi3k inhibitors
WO2016134668A1 (en) * 2015-02-28 2016-09-01 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2016149160A1 (en) * 2015-03-15 2016-09-22 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3277667A1 (en) * 2015-03-31 2018-02-07 Synthon B.V. Improved process for preparing idelalisib
CN106146502B (en) * 2015-04-09 2019-01-04 上海医药工业研究院 End for Larry this synthetic method and prepare intermediate
CN106146352A (en) * 2015-04-16 2016-11-23 上海医药工业研究院 Idelalisib intermediate and preparation method thereof
CN106146411A (en) * 2015-04-16 2016-11-23 上海医药工业研究院 (S) preparation method of-2-(1-amino-propyl)-5-fluoro-3-phenyl-3H-quinazoline-4-one
CN106279171A (en) * 2015-06-09 2017-01-04 南京安源生物医药科技有限公司 A kind of preparation method of Idelalisib
JP2018527362A (en) * 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. Substituted heteroaryl compounds and methods of use
WO2017087445A1 (en) * 2015-11-17 2017-05-26 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
CN105669733A (en) * 2016-01-29 2016-06-15 上海毕路得医药科技有限公司 Synthetic method of 1-methyl-1H-pyrazole-3-boronic acid pinacol ester
WO2017130221A1 (en) * 2016-01-29 2017-08-03 Sun Pharmaceutical Industries Limited Improved process for the preparation of idelalisib
EP3411376A1 (en) * 2016-02-03 2018-12-12 Lupin Limited A process for the preparation of phosphatidylinositol 3-kinase inhibitor
WO2017191608A1 (en) * 2016-05-05 2017-11-09 Laurus Labs Limited Novel process for preparation of idelalisib
KR101932146B1 (en) * 2016-07-14 2018-12-24 주식회사 바이오웨이 Novel Quinazolinone derivatives as PI3K inhibitors, and pharmaceutical composition comprising the same
CN107056810B (en) * 2017-02-09 2019-04-26 广东省中医院 A kind of preparation method of Carbostyril carboxylic acid derivatives

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (en) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide and pharmaceutically acceptable salts and esters (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
CA2133439C (en) 1992-04-02 2005-07-26 Siegfried Benjamin Christensen, Iv Compounds useful for treating allergic and inflammatory diseases
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
CN1070849C (en) 1994-06-15 2001-09-12 惠尔康基金会集团公司 Enzyme inhibitors
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
AT219934T (en) 1995-04-14 2002-07-15 Smithkline Beecham Corp Metered dose inhaler for albuterol
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AT212993T (en) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine and process for their manufacture
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PT892789E (en) 1996-04-12 2002-07-31 Warner Lambert Co Irreversive inhibitors of tyrosine kinases
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
DE69734513T2 (en) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituted tricycl derivatives for the treatment of hyperproliferative diseases
JP2001500851A (en) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト Intermediate products obtained during the course of production and manufacturing epothilone
JP2002513445A (en) 1996-09-06 2002-05-08 オブデュキャット、アクチボラグ Anisotropic etching method structure in the conductive material
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PL193229B1 (en) 1996-11-18 2007-01-31 Gesellschaft für Biotechnologische Forschung mbH Epothylones c,d,e & f, method of obtaining them and their application as a cytostatic agents as wel as plant protection products
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (en) 1997-05-30 1998-12-10 Schering Ag nonsteroidal progestins
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag Crystal modification a N-phenyl-2- pyrimidinamine, processes for their manufacture and use
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
CA2339961C (en) 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
CN100381566C (en) 1998-11-20 2008-04-16 科森生物科学公司 Recombinant methods and materials for producing epothilone and eopthilone derivatives
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
CA2371273A1 (en) 1999-05-04 2000-11-09 Andrew Fensome Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa New derivatives of quinuclidine and pharmaceutical compositions that contain them.
CO5180649A1 (en) 1999-09-01 2002-07-30 Abbott Lab Receptor antagonists of glucocorticoids for the treatment of diabetes for the treatment of diabetes
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6518277B1 (en) 2000-04-25 2003-02-11 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag Hydroxamate compounds as inhibitors of histone deacetylase (HDA)
JP5089846B2 (en) 2000-09-29 2012-12-05 グラクソ グループ リミテッドGlaxo Group Limited Morpholine-acetamide derivatives for treating inflammatory diseases
CA2428133C (en) 2000-11-07 2009-12-29 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
ES2276038T3 (en) 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimetics of glucocorticoids, methods for obtaining them, pharmaceutical formulations containing themselves and uses of the same.
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
AT381333T (en) 2002-03-26 2008-01-15 Boehringer Ingelheim Pharma Glucocorticoid mimetics, their preparation, pharmaceutical compositions and use
US7268152B2 (en) 2002-03-26 2007-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (en) 2002-04-02 2003-12-18 Schering Ag Quinoline and isoquinoline derivatives, a pharmaceutical agent and their use as anti-inflammatory agents
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
US7282591B2 (en) 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004005229A1 (en) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
PL375442A1 (en) 2002-07-18 2005-11-28 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP4520309B2 (en) 2002-09-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション Octahydro-2-H-naphtho [1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
HU0500844A2 (en) 2002-12-09 2007-08-28 Univ Texas Methods for selectively inhibiting janus tyrosine kinase 3(jak3)
US8752543B2 (en) 2003-11-03 2014-06-17 Glaxo Group Limited Fluid dispensing device
WO2005066156A1 (en) 2004-01-12 2005-07-21 Cytopia Research Pty Ltd Selective kinase inhibitors
WO2005095382A1 (en) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Anti-tumor agent
USRE44638E1 (en) 2004-05-13 2013-12-10 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
JP4660553B2 (en) 2004-10-19 2011-03-30 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Quinoline derivatives
JP2010513567A (en) * 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp Quinoline derivatives as inhibitors of PI3 kinase
US20110021541A1 (en) 2007-11-13 2011-01-27 White Stephen L Inhibitors of human phosphatidyl-inositol 3-kinase delta
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
EA019499B1 (en) * 2009-03-24 2014-04-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン, エルエルシー Heterocyclic compounds and uses thereof
UY33304A (en) * 2010-04-02 2011-10-31 Amgen Inc Heterocyclic compounds and their uses
ES2593256T3 (en) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulations
EP2718270A2 (en) * 2011-06-10 2014-04-16 Merck Patent GmbH Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US20130143902A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013116562A1 (en) * 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
CN104768952B (en) 2012-08-08 2016-10-19 山东亨利医药科技有限责任公司 PI3K δ inhibitor
GEP201706623B (en) 2012-10-16 2017-02-10 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors
BR112015014592A2 (en) 2012-12-21 2017-07-11 Gilead Calistoga Llc compound, pharmaceutical composition, and method for treating a human
CA2895782C (en) 2012-12-21 2017-08-22 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2014106800A2 (en) 2013-01-04 2014-07-10 Aurigene Discovery Technologies Limited Substituted 2-amino pyrimidine derivatives as kinase inhibitors
AR094797A1 (en) 2013-02-15 2015-08-26 Almirall Sa Pyrrolotriazine derivatives as inhibitors of PI3K
US9216985B2 (en) 2013-03-28 2015-12-22 Scifluor Life Sciences, Inc. 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
SI3008053T1 (en) 2013-06-14 2018-06-29 Gilead Calistoga Llc Phosphatidylinositol 3-kinase inhibitors
RU2683793C2 (en) * 2013-09-22 2019-04-02 Калитор Сайенсез, ЛЛС Substituted aminopyrimidine compounds and methods of use

Also Published As

Publication number Publication date
RU2016114866A (en) 2017-10-25
KR20160060100A (en) 2016-05-27
WO2015042078A2 (en) 2015-03-26
MX2016003457A (en) 2017-05-25
US20150087658A1 (en) 2015-03-26
AU2014321419B2 (en) 2017-06-15
US20160318913A1 (en) 2016-11-03
AU2014321420A1 (en) 2016-01-28
US9512114B2 (en) 2016-12-06
SG11201600707QA (en) 2016-02-26
RU2016115082A (en) 2017-10-25
WO2015042497A3 (en) 2015-06-04
RU2675105C2 (en) 2018-12-17
WO2015042077A1 (en) 2015-03-26
AU2014321420B2 (en) 2017-06-15
JP2016530338A (en) 2016-09-29
JP2016534146A (en) 2016-11-04
WO2015042078A3 (en) 2015-05-28
MX2016003456A (en) 2017-05-25
RU2683793C2 (en) 2019-04-02
EP3046563A4 (en) 2017-02-15
KR20160058889A (en) 2016-05-25
US9518046B2 (en) 2016-12-13
JP6494633B2 (en) 2019-04-03
EP3046921A4 (en) 2017-02-22
WO2015042497A2 (en) 2015-03-26
US9670194B2 (en) 2017-06-06
RU2675105C9 (en) 2019-01-09
CA2920059A1 (en) 2015-03-26
RU2016114866A3 (en) 2018-06-25
EP3046563B1 (en) 2019-05-29
CA2918938A1 (en) 2015-03-26
EP3046563A1 (en) 2016-07-27
RU2016115082A3 (en) 2018-07-25
US20150087663A1 (en) 2015-03-26
AU2014321419A1 (en) 2016-01-28
JP6494634B2 (en) 2019-04-03
EP3046921A2 (en) 2016-07-27
WO2015042078A8 (en) 2016-01-28
US20160318914A1 (en) 2016-11-03
US9657007B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
HK1224478A1 (en) Reduction of user plane congestion
EP2968075A4 (en) Networked management of dispensables
EP2953474A4 (en) Compositions and methods
HK1221486A1 (en) Compositions and methods
SG11201602662YA (en) Inhibitors of kras g12c
HK1218560A1 (en) Compositions and methods
EP2997770A4 (en) Methods of discovery and measurements for small cellsinofdm/ofdmasystems
PT2970265T (en) Heterocyclic compounds and uses thereof
EP3065875A4 (en) Bioprinter and methods of using same
SG11201507478VA (en) Heteroaryl compounds and uses thereof
HK1215361A1 (en) Attachment apparatuses and associated methods of use and manufacture
IL243479D0 (en) Novel quinazolinones as bromodomain inhibitors
EP2970307A4 (en) Pyrazolo compounds and uses thereof
HK1211866A1 (en) Antioxidant compositions and methods of using the same
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
HUE040111T2 (en) Compounds and their methods of use
SG11201507395PA (en) Inhibitors of the kynurenine pathway
IL243420D0 (en) Heterocyclic compounds and uses thereof
EP2964115A4 (en) Bone fastener and methods of use
EP2990404A4 (en) Tetrazolinone compound and use of same
TWI560180B (en) Substituted benzamides and methods of use thereof
IL246221D0 (en) Indazoles and use thereof
EP3046921A4 (en) Substituted aminopyrimidine compounds and methods of use
EP3083606A4 (en) Pyrimidines and use thereof
ZA201505911B (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof